

IRB

ETHICS
&
HUMAN RESEARCH

FEATURE ARTICLE

Recontacting Pediatric Research Participants for Consent When They Reach the Age of Majority

Bartha Maria Knoppers, Karine Sénécal, Joanne Boisjoli, Pascal Borry, Martina C. Cornel, Conrad V. Fernandez, Jasjote Grewal, Ingrid A. Holm, Erin Nelson, Wim Pinxten, Mahsa Shabani, Anne Marie Tassé, Ma'n Zawati, and Ellen Wright Clayton, on behalf of the P3G International Paediatric Research Platform **1**

Incident Reports and Corrective Actions Received by OHRP

Kemnique Ramnath, Sarita Cheaves, Lisa Buchanan, Kristina Borrer, and Marinna Banks-Shields **10**

2016 MANUSCRIPT REVIEWERS **9****2016 INDEX **16****

A PUBLICATION OF
THE HASTINGS
CENTER



FEATURE ARTICLE

Recontacting Pediatric Research Participants for Consent When They Reach the Age of Majority

BY BARTHA MARIA KNOPPERS, KARINE SÉNÉCAL, JOANNE BOISJOLI, PASCAL BORRY, MARTINA C. CORNEL, CONRAD V. FERNANDEZ, JASJOTE GREWAL, INGRID A. HOLM, ERIN NELSON, WIM PINXTEN, MAHSA SHABANI, ANNE MARIE TASSÉ, MA'N ZAWATI, AND ELLEN WRIGHT CLAYTON, ON BEHALF OF THE P3G INTERNATIONAL PAEDIATRIC RESEARCH PLATFORM

Pediatric research raises particular ethical and legal issues due to the fact that children are presumed to have insufficient cognitive ability to consent to participate in research.¹ In some countries the legal age of majority is recognized as the age at which children can provide consent for research participation, though in others the age of consent for research is established by policy guidance which stipulates an age of consent or sets the criteria for determining cognitive capacity (maturity). For children who have not reached the age of consent as established by law or policy, parents (or legal guardians) must authorize their participation. Depending on their age and maturity, children whose parents or guardians authorize research participation may be asked to assent to being enrolled in a study.

The ethical and legal norms

governing research generally maintain that consent is a continuing process.² Research involving children may include studies spread over a number of years (e.g., biobank or longitudinal studies). Thus, it is likely that children who mature during the course of a study acquire the cognitive capacity to decide whether or not they want to continue their participation. The purpose of this paper is to explore the issue of whether, to satisfy the ethical and legal norms of consent for research, participants in pediatric studies who attain the age of majority after their parents or guardians enroll them in a study should be “recontacted” to obtain their consent to remain in it. After summarizing the legal and policy landscape regarding the age of consent for research participation and clinical care, we explain why the issue of recontacting participants of pediatric research when they reach the age of majority is important and ask whether there is an ethical obli-

Knoppers BA, Sénécal K, Boisjoli J et al. Recontacting pediatric research participants for consent when they reach the age of majority. *IRB: Ethics & Human Research* 2016;38(6):1-9.

gation to do so. We then illustrate the complexities of answering this question in three research contexts: longitudinal pediatric studies (which could include biobanking), pediatric clinical trials, and possible future research with newborn screening bloodspots conducted during the lifetime of individuals' whose bloodspots are used.

Legal Age of Majority for Consent in Research and Clinical Settings

Very few countries explicitly legislate an age of majority specific to consent in the research context.³ In the province of Quebec in Canada, amendments to the Civil Code in 2014 stipulate that a local research ethics committee may allow minors aged 14 years or over to independently give consent to research, but only if the research is of minimal risk and the circumstances justify it.⁴ In the Netherlands, minors aged 12 years and older can legally consent to research, but the parents must consent as well, thus creating a form of dual consent up to 16 or 18 years of age, depending on the type of research and on contextual issues in the clinical setting.⁵

In the context of clinical trials, the 2014 European Union (E.U.) Clinical Trials Regulation provides some guidance for minors by simply mandating that consent should be obtained upon achieving “legal competence”: “If during a clinical trial the minor reaches the age of legal competence to give informed consent as defined in the law of the Member State concerned, his or her express informed consent shall be obtained before that subject can continue to participate in the clinical trial.”⁶ However, other than this clinical trial legislation, which is binding in all E.U. countries and a handful of countries that specifically legislate the age of majority for research, there is little guidance regarding the legal determination of “majority” in the research context,

and so the legal age of majority for adulthood is generally relied on.

Some countries fill this legislative void by using the ethics and professional policies that govern research and allow for a professional case-by-case determination of maturity. In these countries, researchers need to determine whether the adolescent understands not only the potential risks but also the impact, long-term consequences, and lack of personal benefit of participation.⁷ For example, the Canadian Paediatric Society states that “the capacity to provide meaningful consent matures beyond 14 years of age but is very limited before nine years of age. This points to a group of 9- to 14-year-olds who will be in transition—some fully able to provide consent and some unable, despite their physical advances in maturity.”⁸ Similarly, the Royal College of Paediatrics and Child Health in the United Kingdom states that the acquisition of capacity to consent to research is a developmental continuum and that children over 12 to 14 years of age may have near-adult capacity.⁹ In the United States, however, parental permission is required for research participation by minors, with only rare exceptions.¹⁰

In the clinical care context, a few countries have specifically legislated the age of capacity to consent for clinical care. This legal age is often set lower than the general legal age of majority for other activities, such as voting or driving. In the absence of further legal guidance, this leaves open the question as to the type of medical interventions that are covered and, importantly, whether in these countries the same clinical legal age could apply in the context of research. Setting a legal age for consent to medical care accommodates the medical interests of minors such as their contraceptive needs and other sensitive personal health decisions in that parental authorization is not needed.¹¹ While this clarification is helpful, then, for

minors seeking medical care, can it be “imported” into the research context?

If not legislated at a fixed age, capacity to consent for clinical decision-making can be based on this “mature minor” approach set by professional guidance or by the courts (e.g., the Gillick competency test for minors under the age of 16 in the United Kingdom if certain conditions are met).¹² Medical care legislation can also incorporate this “mature minor” rule, as is the case in Ontario, Canada, thus allowing by law for a determination of capacity to consent in the clinical context on a case-by-case basis.¹³

Recontacting Pediatric Participants

The issue of recontacting participants of pediatric research when they reach the age of majority is important for several reasons.¹⁴ Among them, longitudinal studies and studies of large population cohorts are becoming more common. In addition, data are being stored for longer durations and increasingly shared in larger data sets. This is especially true with the recent emphasis on biobanks that collect and store (sometimes indefinitely) genomic and phenotypic data from medical records and tissue samples. Adolescents are unique stakeholders in this “recontact to consent” debate by virtue of their de facto increasing capacity to understand the risks and benefits of the research in which they are enrolled, or by virtue of being legally presumed capable of doing so at a certain age. Recontact to consent at the age of majority could be seen as the extension of the recognition that consent is a continuing process.¹⁵ According to this principle, when participants acquire the capacity to consent, they have the right to decide either to continue taking part or to withdraw their parents' proxy consent.¹⁶ Thus, as children mature, their assent to participate in research

should be sought,¹⁷ and when these participants reach the age of majority, their consent should be sought as well.¹⁸ However, this approach is attended by practical concerns, such as its viability, to say nothing of its impact on the research project.¹⁹

From an ethical point of view, it could also be argued that the interests in maintaining research data sets and avoiding attrition from participants cannot override the rights of research participants. Respect for persons, and for their autonomy and voluntariness, requires that informed consent be obtained.

However, a more flexible approach could be that, when youths attain the capacity to give consent, their right to withdraw from research remains but formal recontact for another explicit consent to continue to participate is not required.²⁰

Of note is that the 1989 *United Nations Convention on the Rights of the Child* states that the best interests of children are “a primary consideration”²¹ and that children have a right to be heard.²² The “best interests of the child principle” should guide all decisions in research and the clinic concerning minors.²³ Thus, while parents can legitimately exercise authority over their children, decisions in research and the clinic concerning minors are guided by the “best interests of child” principle. Interpretive guidance on this principle for the research setting includes language to the effect that researchers should determine whether a minor recruited for research is capable of forming an opinion, can exercise discernment, or is able to assess the material risks and benefits as well as the long-term effects of participating in research, and this in a context that permits expressing an informed decision.

As mentioned, the differing terminology, definitions, and requirements in the context of research include obtaining the assent of minors at an early age when ap-

propriate, irrespective of the issue of legal majority. Moreover, in the last decade, there has been a conceptual shift first from parental (or legal guardian) “consent” to “authorization,” then to parental “permission,”²⁴ and now to parental “responsibility.” This is reflected in the proposed 2018 “EU Data Protection Regulation” on consent to the use of data, which holds that it “shall only be lawful if and to the extent that such consent is given or authorized by the holder of parental responsibility over the child or is

Longitudinal pediatric studies, pediatric clinical trials, and research with newborn screening bloodspots are research contexts that reveal the complexities of determining whether there is an ethical obligation to recontact pediatric participants when they reach the age of majority.

given by the child in circumstances where it is treated as valid by Union or Member State Law.”²⁵

Notwithstanding these changes in the terms used to describe the role of parents, it bears noting that the ambit of parental authority over research or clinical decisions may be limited in certain contexts. This is exemplified in the very recent controversy on both the return of genomic research results to parents and on ensuing professional obligations. While return of results is not the focus of this paper, this controversy serves to illustrate the narrowing ambit of parental rights. Indeed, both in Europe and Canada, according to professional guidance, parents cannot refuse the return of clinically actionable results (i.e., when prevention or treatment is available during childhood).²⁶ Yet,

in 2015, the American College of Medical Genetics and Genomics issued guidelines concerning clinical (not research) testing using next-generation sequencing that allow parents to opt out of receiving results or secondary findings concerning their child prior to undergoing genetic testing for a specific condition.²⁷ Later in the same year, the American Society of Human Genetics (ASHG) recommended that, “in general, parents should be able to decline to receive secondary findings in advance of genetic testing.” However, it recognized that “when there is strong evidence that a secondary finding has urgent and serious implications for a child’s health and welfare, and effective action can be taken to mitigate that threat,” the clinician should communicate those findings to parents or guardians “regardless of the general preferences stated by the parents.”²⁸ Adoption of this ASHG approach in the U.S. would put the country in line with Europe and Canada, whose approaches similarly limit the scope of parental authority concerning medically actionable results during childhood.

Recontact: Three Illustrative Contexts

For the purposes of our contextual analysis, we use the terms “age of majority” or “maturity” to indicate that someone has attained the status of a “competent minor,” irrespective of jurisdiction. We have chosen to examine the concept of the competent minor and recontact for purpose of consent in three contexts: 1) longitudinal, pediatric cohorts that could include biobanks, 2) the “classical” pediatric clinical trial where data and samples from children may still be in use when participants become competent minors, and 3) the potential use of public health newborn screening bloodspots (traditionally collected for monogenic disorders) in research.

■ *Longitudinal, pediatric cohorts that could include biobanks.*

Pediatric longitudinal cohort studies usually have ongoing contact with the children enrolled. For example, membership in some cohorts begins in utero or at birth. Thus, participants will be involved during different stages of their development, perhaps well beyond the age of majority. As a result, there may be more opportunity to accurately determine maturity or respect research majority where legally fixed. Some longitudinal cohorts have associated databases and biobanks that serve as resources for future research.

The LifeLines cohort study in the Netherlands (which includes a biobank), has minors who are 12 years old sign a consent form together with at least one parent. LifeLines provides opportunities for interaction between researchers and minors, and recontact has specifically been integrated into the study protocol. When participants reach the age of 18, LifeLines sends them a recontact birthday letter requesting their consent for ongoing inclusion in the adult cohort of the study.²⁹ The Avon Longitudinal Study of Parents and Children (ALSPAC) in the U.K.³⁰ is another longitudinal cohort with a biobank. It has a policy of recontacting participants when they turn 18. In a study it conducted about the recontact issue, the ALSPAC found no evidence that the communication method used to recontact participants (phone, postcard, designed packs³¹) influenced the consent decision of these “now adults.”³²

Another example is the Canadian Health Measures Survey (CHMS), under the jurisdiction of Statistics Canada. Since 2007, the CHMS has included children from age 6 years onwards, as well as adults. An unpublished report from Statistics Canada indicates that the CHMS adopted a policy of recontact for consent at age 14 years but had a nonresponse rate averaging 72%

after the first contact attempt, dropping to 33% with additional recontact attempts spanning over several months. These averages are from data collected over four years. Counted as nonresponsive were those who could not be contacted and a small number who were contacted but provided no answer.

In 2011, the Office of the Privacy Commissioner (OPC) of Canada responded to a privacy impact assessment submitted by Statistics Canada. It held that the absence of an explicit consent at age 14 years, including in the event of the inability to contact, was the equivalent of no consent from the individual and should result in the destruction of that person’s biospecimens and data. Attrition is a serious issue for pediatric longitudinal cohorts where childhood development is under study and participants are considered representative of the general population (i.e., not disease specific). To date, no biospecimens or data have been destroyed. There have been ongoing discussions with the OPC and the Research Ethics Board of Health Canada and with the Public Health Agency of Canada aimed at achieving a feasible approach to recontacting youth respondents while maintaining the integrity of the pediatric data. Statistics Canada agrees that the study should involve participants in their own decision-making process when they reach 14 years of age and is now adopting a recontact process with a notification and opt-out opportunity. This notification letter will explain the survey, remind participants that their parents consented for them, and tell them they can withdraw if so desired.

The Canadian Tri-Council Policy Statement³³ on ethical conduct for research involving humans mandates that “if children mature sufficiently to decide on their own behalf (subject to legal requirements), the researcher must seek the children’s autonomous consent in order for

their participation to continue.”³⁴ Furthermore, it states that “when authorization for participation was granted by an authorized third party and a participant acquires or regains decision making capacity, the researcher should promptly seek the participant’s consent as a condition of continuing participation.”³⁵

Some studies set a specific age for recontacting minor participants. For example, in Norway, children are notified at 15 years of age of their inclusion in the Norwegian Mother and Child Cohort, and consent is requested when they reach age 18.³⁶ For the Saudi Biobank, there is no recontact at 18 years of age, but at that age, withdrawal from research is possible: “[c]hildren will know about their participation either when they give assent personally or when their guardians notify them about participation.”³⁷ In the U.S., some have argued that the current research regulations may not require obtaining new consent upon reaching majority if all the data have already been collected and are being managed appropriately.³⁸ The provisions of the Notice of Proposed Rulemaking to amend the U.S. research regulations would alter these rules, requiring consent at the age of majority to continue to collect new biospecimens.³⁹

The examples from longitudinal pediatric cohorts are indicative of the patchwork of approaches currently in use around the world. As concerns biobanking activity specifically, the Recommendation 2016(6) of the Committee of Ministers of the Council of Europe holds that “where a person not able to consent . . . attains . . . the capacity to consent, reasonable efforts should be made to seek the consent of that person for continued storage and research use of his or her biological materials.”⁴⁰ The guidelines the Organisation for Economic Co-operation and Development issued in 2009, “Guidelines on Human Biobanks and Genetic Research Da-

tabases,”⁴¹ advise without further elaboration that “[t]he operators of HBGRDs involving participants who are minors or with impaired decision-making capacity should have a clearly articulated policy on what steps will be taken, in accordance with applicable law and ethical principles, once such participants become legally competent to consent.”⁴²

■ **Clinical trials.** Clinical trials that involve the administration of drugs, devices, or interventions during a specified period differ significantly from longitudinal research that is largely epidemiological in nature. For an ongoing clinical trial involving children or minors, a research team might be recontacting a competent minor (now mature adolescent) for the purpose of obtaining his or her consent to ongoing participation, including study-specific interventions and ongoing collection of data. Alternatively, the research team might contact a now mature adolescent in order to share a summary of the results of the research in which the individual has taken part; in this case, recontact would serve as a reminder or notification of the adolescent’s ongoing involvement and may influence his or her decision to continue participation.

Some commentators contend that there is an ethical imperative to provide to all research participants, including parents and competent minors, a summary of overall research findings, whether positive or negative,⁴³ or at least inform them where to find such results (e.g., on a website). The ethical justifications for the offer of aggregate results are various but include affirming the value of research participation, educating participants and the public about the research process, and building trust in the research enterprise.⁴⁴ Such results may be material to an individual’s decision to continue participation. Further, making such information available acknowledges the important role

the participant has played in the research and disseminates accurate scientific knowledge related to the study findings.

An example of such ongoing communication of general results and its possible influence on continued participation is found in the approach of the Children’s Oncology Group (COG)⁴⁵ involving clinical trials with both biological and biobanking aims. This ongoing contact led COG to require that researchers obtain consent at the age of majority (18 years) or sooner if the minor demonstrates adequate maturity to consent to continued participation in COG research.

Despite this COG example, generally, the period for recontact in the context of clinical trials is more limited than in longitudinal studies, as the studies are time limited. During that period, however, interaction between the researcher and the minor is more intense and so offers greater opportunities for the determination of maturity for recontact for consent.

■ **Newborn screening and research.** Health-related screening is defined as “[t]he presumptive identification of unrecognized disease or defect by the application of tests, examinations or other procedures which can be applied rapidly. Screening tests sort out apparently well persons who probably have a disease from those who probably do not. A screening test is not intended to be diagnostic. Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment.”⁴⁶ Today, newborn screening (NBS) is not only part of pediatric health care but is also becoming a source of biospecimens and data for research interests that go beyond quality assurance needs.⁴⁷ In some sense, storage of NBS blood spots is a form of pediatric biobanking.⁴⁸

NBS is a public health mandate and is standard pediatric care in most industrialized countries. It is

the storage or research use of NBS bloodspots without consent that attracts controversy.⁴⁹ In the U.S., when leftover blood spots are stored or to be used for research, parental permission often is now required.⁵⁰ Seeking parental permission for storage of or research on leftover bloodspots is a separate issue from the right of the asymptomatic, at-risk newborn to be identified and treated through screening programs irrespective of parental wishes.⁵¹ Hens and colleagues maintain that “biobanks should have a policy about returning information about preventable or treatable conditions of early onset when participants are minors” and that the consent form should contain details of the policy. They go on to say that “the right of parents to receive or not to receive genetic information about their children is limited. In the rare case that information about a preventable or treatable early-onset disease is found, they should be notified regardless of their wishes, providing the findings are subject to assessment of clinical validity and utility.”⁵²

In 2012, the U.S. National Institutes of Health funded four projects to examine the ramifications of applying next-generation sequencing (NGS) technologies in NBS. One project, the Genome Sequence-Based Screening for Newborn Illness and Childhood Risk, also known as the BabySeq project, is randomizing babies within two cohorts, a healthy newborn cohort and an ill newborn cohort, to standard NBS or standard NBS plus NGS. In the arm that receives NGS, pathogenic variants in genes with strong evidence for causing highly penetrant childhood-onset disease, and carrier status for childhood-onset diseases, are reported back to families. The BabySeq project is studying the impact of the return of this genomic information to parents of newborns and their physicians.⁵³ However, there will be many unknowns, including what

happens to the communication of other results as the child matures. As is the case with most clinical trials, BabySeq has only short-term funding, although the hope is that long-term follow-up will be feasible so that this latter question, as well as others, can be addressed. Notably, in the hope that these long-term questions can be addressed with future funding, BabySeq is obtaining parental permission to recontact participating minors to obtain assent at 13 years of age and consent at 18 years.

Achieving Recontact?

Before determining the potential duties of researchers in regard to recontacting participants of pediatric research for consent at majority or maturity, we distinguished three different contexts based on the risks and benefits present in each: longitudinal studies, short-term research projects, and secondary research with newborn bloodspots. For the purposes of our discussion, we presume that withdrawal from ongoing research participation is always an option, although we recognize that anonymized or published data cannot be withdrawn. Indeed, recontact provides an opportunity to operationalize the choice to withdraw or to refuse further use of participants' data or biospecimens.

In some longitudinal research designs, contact with research participants is planned (such as for follow-up or repeat questionnaires or measurements). Other longitudinal studies keep participants informed of the evolution of the study by sending newsletters or via a website. Such studies could also foresee recontact in the original parental authorization for either the future assent of the child or (where applicable) to ask minors for their own consent when they reach majority or maturity. In some studies, permission to recontact to obtain informed consent from minors in the future could be part

of the original consent, or permission to recontact could be obtained later at a convenient time, such as with repeat questionnaires or updates, thus decreasing privacy concerns. In other studies, such as biobank-related research, posting general research-project information on the Internet and making reasonable efforts to notify participants at majority that they have the option of opting out of future research could be considered sufficient. However, when active participation by the minor ceases for a significant period prior to majority or when the investigator is no longer in touch with the family, the feasibility, practicability, or costs of recontact may make it unrealistic, and obtaining a research ethics board (REB) waiver for recontact may be possible.

Most pediatric research falls in the category of "research with limited duration." While prospective consent to recontact can be obtained in short-term research, realizing such promises can nevertheless be problematic, for example, if there is lack of ongoing funding or if it is impractical or unfeasible to recontact participants. Yet when it is possible to do, it could be argued that from an ethical perspective, respect for individuals' exercise of autonomy mandates recontact. However, if research participants are to be recontacted to obtain consent at majority, it would be important to be transparent about such future recontact and inform parents during the consent process. Some research involves parents as well as their children, and parents could feel uncomfortable that their child is confronted with sensitive data.⁵⁴

There are arguments both for and against recontact for autonomous decision-making by the research participants in this context. At present, this issue may not be well addressed in consent forms, as demonstrated in a Canadian review of pediatric research consent forms. This study revealed that 49% of a

selected sample of consent forms used in a wide variety of Canadian pediatric research do not address the potential for future recontact at the legal age of majority.⁵⁵ This is contrary to the ethical norms governing research involving humans in Canada.⁵⁶ In contrast, a review of six birth cohorts in North America and Europe showed that studies that follow children past early childhood and into the adolescent years recognize a need to consider the wishes of the maturing child and to respect their autonomous choices when they attain age of legal majority.⁵⁷ Another qualitative study that involved interviewing young adults who were former pediatric oncology patients with stored research biospecimens revealed their wish (when feasible) to be asked for consent upon adulthood for continued research with their data. They did, however, consider it acceptable to continue to conduct research if participants could not be located.⁵⁸ Therefore, again, even in short-term research, it seems that an option for recontact for consent at maturity or majority should be discussed during enrollment. However, when recontact is not possible, a waiver could be sought from an REB, thus allowing ongoing use of biospecimens and data.

The use of pediatric biobanked legacy collections for secondary research often involves data or biospecimens from individuals who were enrolled as children and now may have reached majority. Presuming that no specific recontact choices were made in the original consent and in the absence of a broad consent covering future secondary research with legacy biospecimens, either all participants would have to be recontacted, or an REB waiver of recontact would have to be sought.⁵⁹ Attention should be paid to the fact that recontact can be burdensome or cause disproportionate expense and effort for researchers. The implications of

recontact on personal and familial privacy and on overall researcher obligations are unknown. Would a “secondary” researcher have any duty to recontact, notify, or obtain consent from the “now adult”? The content of the original parental consent would govern this situation, especially as concerns data-use limitations.

Conclusion

As a best practice, we suggest that researchers address recontact issues at the time of the original enrollment of children in research and clearly state what will happen, when, and why. This could include no recontact, anonymization of biospecimens and data before further research, or even destruction of data and biospecimens at the age of majority (the latter two approaches potentially compromising the scientific aims⁶⁰). In other studies, where researchers are in dynamic and ongoing communication with their minor participants, the general rule is to ask the participant at maturity or majority for his or her consent to continued participation. At a minimum, it is reasonable to notify the individual with information concerning participation and to provide the possibility of opting out and the procedures for doing so. For now, researchers’ emerging duty to recontact will inevitably be circumscribed by both the practical and principled considerations we have raised.

An obligation to recontact—a “must” about this step—is laudable and respectful of first-person consent; however, efforts to do this should be balanced with the feasibility and cost (both human and economic) entailed.⁶¹ Although some would argue that without exception it should be mandatory that “at the age of majority the participant in principle can re-consent or withdraw his/her consent,” even authors taking this position concede that in reality only a best effort can be applied.⁶² The ethical acceptabil-

ity of this is supported by empirical evidence that many participants are comfortable with having their data used in the event that recontact is difficult.⁶³

It is important to consider the vulnerability of adolescents, the difficulties involved in finding them, the inability to judge the “reality” of presumed maturity, and the infringement of their privacy as “now adults.” The risks of recontact in terms of both sociopsychological and familial impact should not be underestimated. The burdens, costs, and inefficiency of such “tracking” are very real. Is there a reasonable likelihood that such contact will make a difference? What are the risks of not recontacting? In situations where there was no ongoing communication with the individual minor, one could argue that respect for the autonomy of the presumed “now adult” could be limited to reasonable efforts to notify or remind parents (on websites or by letters) to tell their “now adults” that they were enrolled in research. Again, the costs and effectiveness of such an approach merit evaluation.

Overall, we maintain that the anticipated benefits of recontact should outweigh the risks and that the decision to recontact should be proportionate to the specific context, the nature of the research, and the best interests and expectations of the then minors and their families when the individuals were first enrolled even though they are now adults.

■ **Bartha Maria Knoppers, PhD**, is the director of the Centre of Genomics and Policy and a professor on the Faculty of Medicine at McGill University; **Karine Sénécal, LLM**, is an academic associate at the Centre of Genomics and Policy on the Faculty of Medicine in the Department of Human Genetics at McGill University; **Joanne Boisjoli, MLT, ART**, is a biobank coordinator for the Canadian Health Measures Survey of Statistics Canada; **Pascal Borry, PhD**, is an associate professor in the Centre for Biomedical Ethics and Law and in the Department of Public Health and Primary Care at the University of Leuven; **Martina C. Cornel, MD, PhD**, is a professor of community genetics and public health

genomics in the Department of Clinical Genetics at the EMGO Institute for Health and Care Research at VU University Medical Center; **Conrad V. Fernandez, MD, FRCPC**, is a professor and the head of the Division of Pediatric Hematology and Oncology in the IWK Health Centre at Dalhousie University; **Jasjote Grewal, LLB, MA**, is a research fellow in biolaw at the Centre for Ethics and Law in the Life Sciences at Leibniz Universität Hannover; **Ingrid A. Holm, MD, MPH**, is a faculty member in the Division of Genetics and Genomics and the Manton Center for Orphan Diseases Research at Boston Children’s Hospital and is an associate professor of pediatrics at Harvard Medical School; **Erin Nelson, JSD**, is a professor on the Faculty of Law and a fellow of the Health Law Institute at the University of Alberta; **Wim Pinxten, PhD**, is a professor in the Faculty of Medicine and Life Sciences at Hasselt University; **Mahsa Shabani, LLM**, is a PhD candidate at the Centre for Biomedical Ethics and Law and the Department of Public Health and Primary Care at the University of Leuven; **Anne Marie Tassé, LLD**, is the executive director of the Public Population Project in Genomics and Society; **Ma’n Zawati, LLM**, is the executive director of the Centre of Genomics and Policy and an academic associate on the Faculty of Medicine in the Department of Human Genetics at McGill University; and **Ellen Wright Clayton, MD, JD**, is the Craig-Weaver professor of pediatrics, a professor of law, and a professor of health policy and works in the Center for Biomedical Ethics at Vanderbilt University School of Medicine.

Acknowledgments

This work is kindly supported by the Interfaculty Council for Development Co-operation of the University of Leuven, the EUCeLEX project of the European Commission FP7 programme (grant agreement 601806), the FWO (Flanders-Québec) project, and the Ministère de l’Économie, de la Science et de l’Innovation du Québec, PSR-SIIRI-850 (Canada) and Genome Québec.

References

1. Presidential Commission for the Study of Bioethical Issues. *Safeguarding Children: Pediatric Medical Countermeasure Research*. Washington, DC: U.S. Department of Health and Human Services, 2013, p. 26.
2. For example, see Council for International Organizations of Medical Sciences. *International Ethical Guidelines for Biomedical Research Involving Human Subjects*. Geneva: Council for International Organizations of Medical Sciences, 2002, guidelines 4 and 6; Organisation for Economic Co-operation and Development. *OECD Guidelines on Human*

Biobanks and Genetic Research Databases. Paris: Organisation for Economic Co-operation and Development, 2009, s. 4.8-4.10.

3. Alderson P. Competent children? Minors' consent to health care treatment and research. *Social Science & Medicine* 2007;65(11):2272-2283.
4. Quebec. *Civil Code of Québec*, L.R.Q. c. C-1991. art. 21, al. 5.
5. The Netherlands, *Amended Medicinal Research Involving Human Subjects Act (Regulations on medical research involving human subjects)*, 1 March 2006), s. 4-5 [unofficial translation]; see also Norway. Lov om medisinsk og helsefaglig forskning (helseforskningsloven) [the Health Research Act], 20.6. Nr. 44 2008. § 17 and 18.
6. European Commission. *Clinical Trials Regulation (CTR)*. EU No 536/2014, art. 32(3).
7. Clayton EW. How much control do children and adolescents have over genomic testing, parental access to their results, and parental communication of those results to others? *Journal of Law, Medicine & Ethics* 2015;43(3):538-544.
8. Canadian Paediatric Society. Ethical issues in health research in children. *Paediatrics & Child Health* 2008;13(8):707-712. The Canadian Paediatric Society reaffirmed the contents of this document in 2016.
9. Mohdi N, Vohra J, Preston J, et al. Guidance on clinical research involving infants, children and young people: An update for researchers and research ethics committees. *Archives of Disease in Childhood* 2014;99(10):887-891.
10. See ref. 7.
11. For example, the legislated age of medical majority is 15 years in Denmark, 14 years in Portugal, 15 years in Slovenia, and 16 years in Spain. For more information, see Stultiëns, Goffin T, Borry P, et al. Minors and informed consent: A comparative approach. *European Journal of Health Law* 2007;14(1):21-46; Coleman DL, Roseoff PM. The legal authority of mature minors to consent to general medical treatment. *Pediatrics* 2013;131(4):786-793.
12. Gillick competency test for a minor under 16. *Gillick v West Norfolk and Wisbech Area Health Authority* (1985) 3 All ER 402.
13. Ontario. Health Care Consent Act, 1996, S.O. 1996, c. 2, Sched. A. s. 4(1).
14. Wallace SE, Gourna EG, Laurie G, et al. Respecting autonomy over time: Policy and empirical evidence on re-consent in longitudinal biomedical research. *Bioethics* 2015;doi:10.1111/bioe.12165; Brothers KB, Lynch JA, Aufox SA, et al. Practical guidance on informed consent for pediatric participants in a biorepository. *Mayo Clinic* 2014;89(11):1471-1480; Hens K, Van El CE, Borry P, et al. Developing a policy for paediatric biobanks: Principles for good practice. *European Journal of Human Genetics* 2013;21(1):2-7; Giesbertz NAA, Brede-noord AL, van Delden JJM. When children

- become adults: Should biobanks re-contact? *PLOS Medicine* 2016; doi:10.1371/journal.pmed.1001959.
15. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. *Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans*. Ottawa: Secretariat on Responsible Conduct of Research, 2014.
 16. Ries NM. Longitudinal studies involving children and adolescents. In: Avar D, Samuel J, Knoppers BM, *Paediatric Research in Canada*. Montreal: Les Editions Themis, 2009, p. 86.
 17. See ref. 2, Council for International Organizations of Medical Science, 2002, guideline 14.
 18. See ref. 2, Council for International Organizations of Medical Science, 2002, guideline 9; see ref. 15, s. 3.4.
 19. See ref. 16, p. 87.
 20. Council of Europe—Committee of Ministers. Recommendation 2006(4) of the Committee of Ministers to Member States on Research on Biological Materials of Human Origin. Strasbourg, 2006.
 21. United Nations. *Convention on the Rights of the Child*. New York: United Nations, 1989, art. 3.2.
 22. See ref. 21, art. 12.2.
 23. Zawati M, Parry D, Knoppers BM. The best interests of the child and the return of results in genetic research: International comparative perspectives. *BMC Medical Ethics* 2014;15:72.
 24. American Academy of Pediatrics, Committee on Bioethics. Informed consent, parental permission, and child assent in pediatric practice. *Pediatrics* 1995;95(2):314-317.
 25. European Commission. *Proposal for a Regulation of the European Parliament and of the Council on the Protection of Individuals with Regard to the Processing of Personal Data and on the Free Movement of Such Data (General Data Protection Regulation)*. Brussels: European Commission, 2012.
 26. Boycott K, Hartley T, Adam S, et al. The clinical application of genomic-wide sequencing for monogenic diseases in Canada: Position statement of the Canadian College of Medical Genetics. *Journal of Medical Genetics* 2015;52(7):431-437.
 27. American College of Medical Genetics Board of Directors. ACMG policy statement: Updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. *Genetics in Medicine* 2015;17(1):68-69.
 28. Botkin JR, Belmont JW, Berg JS, et al. Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. *American Journal of Human Genetics* 2015;97(1):6-21.
 29. LifeLines. LifeLines in General. <https://www.lifelines.nl/lifelines-research/general>.
 30. University of Bristol. Avon Longitu-

- dinal Study of Parents and Children. www.bristol.ac.uk/alspac.
31. See ref. 14, Brothers et al. 2014.
 32. Boyd A, Tilling K, Cornish R, et al. Professionally designed information materials and telephone reminders improved consent response rates: Evidence from an RCT nested within a cohort study. *Journal of Clinical Epidemiology* 2015;68(8):877-887.
 33. See ref. 15.
 34. See ref. 15.
 35. See ref. 15.
 36. Norwegian Mother and Child Cohort Study, *Revised Protocol*. Oslo: Norwegian Institute of Public Health, 2012, p.11.
 37. Alahmad GH, Dierickx K. Confidentiality, informed consent and children's participation in the Saudi biobank governance: A comparative study. *Eastern Mediterranean Health Journal* 2014;20(11):681-685.
 38. See ref. 7.
 39. Department of Health and Human Services. Notice of Proposed Rule-making. Federal Policy for the Protection of Human Subjects. Federal Register 2015;80(173):53933-54061.
 40. Recommendation CM/Rec(2016)6 of the Committee of Ministers to member States on research on biological materials of human origin (adopted by the Committee of Ministers on 11 May 2016 at the 1256th meeting of the Ministers' Deputies).
 41. See ref. 2, Organisation for Economic Co-operation and Development 2009.
 42. See ref. 2, Organisation for Economic Co-operation and Development 2009.
 43. World Medical Association. Declaration of Helsinki. October 2000. http://www.wma.net/e/policy/17-c_e.html.
 44. Fernandez CV, Kodish E, Weijer C. Returning research results to subjects. An ethical imperative. *IRB: Ethics & Human Research* 2003;25(3):12-19.
 45. Children's Oncology Group. Home-page. <https://www.childrensoncologygroup.org/>.
 46. Wilson JMG, Jungner G. *Principles and Practice of Screening for Disease*. Geneva: World Health Organization, 1968, p. 9.
 47. See ref. 28.
 48. Knoppers BM, Avar D, Sénécal K. Newborn screening programmes: Emerging biobanks? *Norsk Epidemiologi* 2012;21(2):163-168.
 49. Knoppers BM, Sénécal K, Borry P, et al. Whole-genome sequencing in newborn screening programs. *Science Translational Medicine* 2014;6(229):229cm2.
 50. U.S. Congress. 113th Congress (2013-2014). H.R.1281, Newborn Screening Saves Lives Reauthorization Act of 2014, Pub.L. 113-240.
 51. Knoppers BM, Laberge C. *Genetic Screening from Newborns to DNA Typing*. Amsterdam: Elsevier Science Publishers, 1990.
 52. See ref. 14, Hens et al. 2013.
 53. Genomeweb. *Off and Running*. July 2, 2015. <https://www.genomeweb.com/scan/>

THANK YOU TO OUR 2016 MANUSCRIPT REVIEWERS

In addition to members of The Hastings Center staff, the following individuals served as reviewers in 2016 (or late 2015). We apologize if we have missed anyone.

Julie M. Aultman

Northeast Ohio Medical University

Ariella Binik

The Ethox Centre, University of Oxford

Mary Brydon-Miller

University of Cincinnati

Jean Cadigan

University of North Carolina at Chapel Hill

Stephanie Solomon Cargill

Saint Louis University

I. Glenn Cohen

Harvard Law School

Raymond De Vries

University of Michigan Medical School

Conrad Fernandez

Dalhousie University

Paul Ford

Cleveland Clinic

Bruce Gordon

University of Nebraska Medical Center

Gavin W. Hougham

Battelle Advanced Analytics and Health Research

Stephen R. Latham

Yale University

Anne Drapkin Lyerly

University of North Carolina at Chapel Hill

Kathryn Rose Macapagal

Northwestern University

Melinda Moore

Eastern Kentucky University

Elana Newman

University of Tulsa

Gregory S. Ogrinc

Dartmouth College

Barton Palmer

University of California, San Diego

Efthimios Parasidis

The Ohio State University

Lisa S. Parker

University of Pittsburgh

Sean Philpott-Jones

Clarkson University

Rebecca D. Pentz

Emory University

Stuart Rennie

University of North Carolina at Chapel Hill

J. Scott Roberts

University of Michigan

Mark Rothstein

University of Louisville

David Resnik

National Institute of Environmental Health Sciences

Erica Salter

St. Louis University

Monica Schoch-Spana

University of Pittsburgh

Lois Shepherd

University of Virginia

Chris Simon

University of Iowa

Julia Slutsman

National Institutes of Health

Laura Stark

Vanderbilt University

Jon C. Tilburt

Mayo Clinic

Susan Trinidad

University of Washington

Danielle M. Whicher

Patient-Centered Outcomes Research Institute

Benjamin S. Wilfond

Seattle Children's Research Institute
University of Washington

Leslie E. Wolf

Georgia State University

and-running.

54. Paquette ET, Ross LF. Consent is the cornerstone of ethically valid research: Ethical issues in recontacting subjects who enrolled in research as a minor. *American Journal of Bioethics* 2015;15(10):61-63.

55. Dove E, Avard D, Black L. et al. Emerging issues in paediatric health research consent forms in Canada: Working towards best practices. *BMC Medical Ethics* 2013;14:5.

56. See ref. 4, Canadian Institutes of Health Research et al., s. 3.3.

57. Ries N, LeGrandeur J, Caulfield T. Handling ethical, legal and social issues in birth cohort studies involving genetic research: Responses from studies in six countries. *BMC Medical Ethics* 2010;11(4):1-9.

58. Rush A, Battisti R, Barton B, et al. Opinions of young adults on re-consenting for biobanking. *Journal of Pediatrics* 2016;167(4):925-930.

59. 45 CFR 46.116(d)(2016).

60. See ref. 14, Brothers et al. 2014; Resnik DB. Re-consent upon reaching the age of majority: Ethical issues. *Journal of Clinical*

Research Best Practices 2014;10(2).

61. See ref. 14, Brothers et al. 2014, p. 1476.

62. See ref. 14, Hens et al. 2013.

63. Goldenberg AJ, Hull SC, Botkin JR, et al. Pediatric biobanks: Approaching informed consent for continuing research after children grow up. *Journal of Pediatrics* 2011;155(4):578-583; Hens K, Nys H, Cassiman JJ, et al. The storage and use of biological tissue samples from minors for research: A focus group study. *Public Health Genomics* 2011;14(2):68-76.